WallStreetZenWallStreetZen

NASDAQ: HOOK
Hookipa Pharma Inc Stock Forecast, Predictions & Price Target

Analyst price target for HOOK

Based on 2 analysts offering 12 month price targets for Hookipa Pharma Inc.
Min Forecast
$5.00+538.57%
Avg Forecast
$5.50+602.43%
Max Forecast
$6.00+666.28%

Should I buy or sell HOOK stock?

Based on 2 analysts offering ratings for Hookipa Pharma Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their HOOK stock forecasts and price targets.

HOOK stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-06-05
lockedlocked$00.00+00.00%2024-05-21

1 of 1

Forecast return on equity

Is HOOK forecast to generate an efficient return?
Company
-4.73%
Industry
76.1%
Market
79%
HOOK's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is HOOK forecast to generate an efficient return on assets?
Company
-3.39%
Industry
30.96%
HOOK is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

HOOK earnings per share forecast

What is HOOK's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$0.46
Avg 2 year Forecast
-$0.58
Avg 3 year Forecast
-$0.56

HOOK revenue forecast

What is HOOK's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$50.0M-6.57%
Avg 2 year Forecast
$11.9M-77.78%
Avg 3 year Forecast
$15.0M-71.99%
HOOK's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

HOOK revenue growth forecast

How is HOOK forecast to perform vs Biotechnology companies and vs the US market?
Company
-48.06%
Industry
35%
Market
9.85%
HOOK's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
HOOK's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

HOOK vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
HOOK$0.78$5.50+602.43%Buy
ONCY$1.03$4.00+288.35%Buy
SPRO$1.43$7.00+389.51%Buy
KRON$1.28$4.13+222.27%Strong Buy
ENTX$2.19$10.00+356.62%Buy

Hookipa Pharma Stock Forecast FAQ

Is Hookipa Pharma Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: HOOK) stock is to Buy HOOK stock.

Out of 2 analysts, 0 (0%) are recommending HOOK as a Strong Buy, 2 (100%) are recommending HOOK as a Buy, 0 (0%) are recommending HOOK as a Hold, 0 (0%) are recommending HOOK as a Sell, and 0 (0%) are recommending HOOK as a Strong Sell.

If you're new to stock investing, here's how to buy Hookipa Pharma stock.

What is HOOK's earnings growth forecast for 2024-2026?

(NASDAQ: HOOK) Hookipa Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.79%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.61%.

Hookipa Pharma's earnings in 2024 is -$47,517,000.On average, 3 Wall Street analysts forecast HOOK's earnings for 2024 to be -$45,190,514, with the lowest HOOK earnings forecast at -$67,286,073, and the highest HOOK earnings forecast at -$30,674,533. On average, 3 Wall Street analysts forecast HOOK's earnings for 2025 to be -$57,391,062, with the lowest HOOK earnings forecast at -$76,191,582, and the highest HOOK earnings forecast at -$29,685,032.

In 2026, HOOK is forecast to generate -$55,738,595 in earnings, with the lowest earnings forecast at -$75,202,081 and the highest earnings forecast at -$28,695,531.

What is HOOK's revenue growth forecast for 2024-2026?

(NASDAQ: HOOK) Hookipa Pharma's forecast annual revenue growth rate of -48.06% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.85%.

Hookipa Pharma's revenue in 2024 is $53,552,000.On average, 2 Wall Street analysts forecast HOOK's revenue for 2024 to be $4,950,968,604, with the lowest HOOK revenue forecast at $4,835,691,729, and the highest HOOK revenue forecast at $5,066,245,478. On average, 1 Wall Street analysts forecast HOOK's revenue for 2025 to be $1,177,506,273, with the lowest HOOK revenue forecast at $1,177,506,273, and the highest HOOK revenue forecast at $1,177,506,273.

In 2026, HOOK is forecast to generate $1,484,251,605 in revenue, with the lowest revenue forecast at $1,484,251,605 and the highest revenue forecast at $1,484,251,605.

What is HOOK's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: HOOK) forecast ROA is -3.39%, which is lower than the forecast US Biotechnology industry average of 30.96%.

What is HOOK's Price Target?

According to 2 Wall Street analysts that have issued a 1 year HOOK price target, the average HOOK price target is $5.50, with the highest HOOK stock price forecast at $6.00 and the lowest HOOK stock price forecast at $5.00.

On average, Wall Street analysts predict that Hookipa Pharma's share price could reach $5.50 by Jun 5, 2025. The average Hookipa Pharma stock price prediction forecasts a potential upside of 602.43% from the current HOOK share price of $0.78.

What is HOOK's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: HOOK) Hookipa Pharma's current Earnings Per Share (EPS) is -$0.50. On average, analysts forecast that HOOK's EPS will be -$0.46 for 2024, with the lowest EPS forecast at -$0.68, and the highest EPS forecast at -$0.31. On average, analysts forecast that HOOK's EPS will be -$0.58 for 2025, with the lowest EPS forecast at -$0.77, and the highest EPS forecast at -$0.30. In 2026, HOOK's EPS is forecast to hit -$0.56 (min: -$0.76, max: -$0.29).

What is HOOK's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: HOOK) forecast ROE is -4.73%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.